Glenmark Pharmaceuticals has introduced a new fixed-dose triple therapy in India for patients with chronic obstructive pulmonary disease (COPD). The treatment combines three medications—an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA), and a long-acting beta-agonist (LABA)—into a single inhaler, aiming to simplify therapy and improve patient adherence.

COPD is a progressive respiratory condition that affects millions of people in India, often leading to breathlessness, frequent flare-ups, and reduced quality of life. Triple therapy is commonly recommended for patients who continue to experience symptoms or exacerbations despite dual therapy. By offering all three components in one device, Glenmark’s product seeks to reduce treatment burden and support better disease management.

The company stated that the new therapy aligns with global clinical guidelines and could help address a significant unmet need in COPD care. With this launch, Glenmark continues to expand its respiratory portfolio and strengthen its presence in chronic lung disease management.